Amgen Is The Cheapest Biotech - Cramer's Lightning Round (2/18/16)

|
Includes: AMGN, CLDX, FIT, NAT, OHI, TSO
by: SA Editor Mohit Manghnani

Summary

Celldex Therapeutics is a good speculative biotech stock.

Healthcare REITs are breaking down; stay away.

Cramer is not recommending refiners in this environment.

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 18.

Bullish Calls

Amgen (NASDAQ:AMGN): It's one of the cheapest biotech stocks. These have been hated due to the political situation but Cramer likes it.

Celldex Therapeutics (NASDAQ:CLDX): If you want a nice speculative biotech, this is it.

Nordic American Tanker (NYSE:NAT): It has a 13% yield and it looks good in this case since there is a lot of demand for their tankers.

Fitbit (NYSE:FIT): When Fitbit reports, it will not let us down.

Bearish Calls

Omega Healthcare (NYSE:OHI): Healthcare REITs have been breaking down which gets Cramer concerned.

Tesoro (NYSE:TSO): Cramer does not like the refinery stocks right now.

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - It's free and takes only a few seconds to sign up.